A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
NCT ID: NCT07160725
Last Updated: 2026-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
315 participants
INTERVENTIONAL
2025-10-15
2028-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors
NCT01986218
A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors
NCT05217693
Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan
NCT00898716
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
NCT06476808
Phase I Study of BMS-690514 in Japanese Patients With Solid Tumors
NCT00516451
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part 1
BMS-986517
Specified dose on specified days
Part 2: Cohort A
BMS-986517
Specified dose on specified days
Part 2: Cohort B
BMS-986517
Specified dose on specified days
Part 2: Cohort C
BMS-986517
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-986517
Specified dose on specified days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants must have measurable disease by RECIST v1.1 (radiologically measured by the Investigator).
* Participants must have documented histologically or cytologically confirmed advanced, unresectable/metastatic solid tumors, including NSCLC, HNSCC, TNBC, and HR+/HER2- breast cancer.
Exclusion Criteria
* Participants must not have concurrent malignancy (present during Screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment assignment.
* Participants must not have history of serious recurrent infections.
* Participants must not have impaired cardiac function or history of severe heart disease.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 0033
Irvine, California, United States
Local Institution - 0002
Los Angeles, California, United States
Local Institution - 0021
Orange, California, United States
Local Institution - 0008
Pittsburgh, Pennsylvania, United States
Sanford Cancer Center
Sioux Falls, South Dakota, United States
START - Dallas Fort Worth
Fort Worth, Texas, United States
START San Antonio
San Antonio, Texas, United States
START Mountain Region
West Valley City, Utah, United States
Local Institution - 0028
Seattle, Washington, United States
Herlev and Gentofte Hospital
Copenhagen, Capital Region, Denmark
Odense Universitetshospital
Odense, Region Syddanmark, Denmark
Copenhagen University Hospital Rigshospitalet
Copenhagen, , Denmark
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
Local Institution - 0026
Málaga, Andalusia, Spain
Local Institution - 0022
Badalona, Barcelona [Barcelona], Spain
Local Institution - 0024
Barcelona, Barcelona [Barcelona], Spain
Local Institution - 0025
Pamplona, Navarre, Spain
Local Institution - 0027
Madrid, , Spain
Local Institution - 0023
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Role: CONTACT
First line of the email MUST contain the NCT# and Site #.
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Site 0033
Role: primary
Site 0002
Role: primary
Site 0021
Role: primary
Site 0008
Role: primary
Steven Powell, Site 0005
Role: primary
Henry Xiong, Site 0030
Role: primary
Drew Rasco, Site 0020
Role: primary
William McKean, Site 0031
Role: primary
Site 0028
Role: primary
Mogens Boisen, Site 0016
Role: primary
Annette Kodahl, Site 0015
Role: primary
Kristoffer Rohrberg, Site 0017
Role: primary
Noboru Yamamoto, Site 0029
Role: primary
Site 0026
Role: primary
Site 0022
Role: primary
Site 0024
Role: primary
Site 0025
Role: primary
Site 0027
Role: primary
Site 0023
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EU CTR
Identifier Type: OTHER
Identifier Source: secondary_id
WHO
Identifier Type: OTHER
Identifier Source: secondary_id
CA254-0001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.